Wellgistics Health (NASDAQ:WGRX) Accelerates Platform Growth in Q2 With 116 Manufacturer Partnerships, 12,400+ New Products, and 275+ Pharmacies Added to Its Expanding Tech Based Drug Ecosystem
Wellgistics Health (NASDAQ:WGRX), a healthcare technology company, reported strong Q2 2025 operational growth with the addition of 116 new pharmaceutical manufacturer partnerships, over 12,400 new products (NDCs), and 275+ pharmacies to its national platform.
The company's AI-powered infrastructure aims to revolutionize prescription drug delivery by connecting manufacturers directly to pharmacies, providers, employers, and patients. The platform provides comprehensive services including wholesale distribution, digital Rx routing, pharmacy dispensing, and Hub Services such as eligibility verification, prior authorization, and patient engagement.
Wellgistics Health (NASDAQ:WGRX), un'azienda tecnologica nel settore sanitario, ha riportato una forte crescita operativa nel secondo trimestre del 2025 con l'aggiunta di 116 nuove partnership con produttori farmaceutici, oltre 12.400 nuovi prodotti (NDC) e più di 275 farmacie alla sua piattaforma nazionale.
L'infrastruttura basata sull'intelligenza artificiale dell'azienda punta a rivoluzionare la distribuzione di farmaci su prescrizione collegando direttamente i produttori a farmacie, fornitori, datori di lavoro e pazienti. La piattaforma offre servizi completi che includono distribuzione all'ingrosso, instradamento digitale delle prescrizioni, dispensazione farmaceutica e servizi Hub come la verifica dell'idoneità, l'autorizzazione preventiva e il coinvolgimento del paziente.
Wellgistics Health (NASDAQ:WGRX), una empresa de tecnología sanitaria, reportó un fuerte crecimiento operativo en el segundo trimestre de 2025 con la incorporación de 116 nuevas asociaciones con fabricantes farmacéuticos, más de 12,400 nuevos productos (NDC) y más de 275 farmacias a su plataforma nacional.
La infraestructura impulsada por inteligencia artificial de la compañía busca revolucionar la entrega de medicamentos con receta conectando directamente a los fabricantes con farmacias, proveedores, empleadores y pacientes. La plataforma ofrece servicios integrales que incluyen distribución mayorista, enrutamiento digital de recetas, dispensación en farmacias y servicios Hub como verificación de elegibilidad, autorización previa y participación del paciente.
Wellgistics Health (NASDAQ:WGRX)는 헬스케어 기술 회사로서 2025년 2분기에 116개의 새로운 제약 제조업체 파트너십, 12,400개 이상의 신규 제품(NDC), 275개 이상의 약국을 자사의 전국 플랫폼에 추가하며 강력한 운영 성장을 보고했습니다.
회사의 인공지능 기반 인프라는 제조업체를 약국, 의료 제공자, 고용주 및 환자와 직접 연결하여 처방약 배송 방식을 혁신하는 것을 목표로 합니다. 이 플랫폼은 도매 유통, 디지털 처방 경로 지정, 약국 조제 및 적격성 확인, 사전 승인, 환자 참여와 같은 허브 서비스 등 포괄적인 서비스를 제공합니다.
Wellgistics Health (NASDAQ:WGRX), une entreprise de technologie de la santé, a annoncé une forte croissance opérationnelle au deuxième trimestre 2025 avec l'ajout de 116 nouveaux partenariats avec des fabricants pharmaceutiques, plus de 12 400 nouveaux produits (NDC) et plus de 275 pharmacies à sa plateforme nationale.
L'infrastructure alimentée par l'intelligence artificielle de la société vise à révolutionner la distribution des médicaments sur ordonnance en connectant directement les fabricants aux pharmacies, prestataires, employeurs et patients. La plateforme offre des services complets incluant la distribution en gros, le routage numérique des ordonnances, la dispensation en pharmacie ainsi que des services Hub tels que la vérification d'éligibilité, l'autorisation préalable et l'engagement des patients.
Wellgistics Health (NASDAQ:WGRX), ein Unternehmen für Gesundheitstechnologie, meldete ein starkes operatives Wachstum im zweiten Quartal 2025 mit der Aufnahme von 116 neuen Partnerschaften mit pharmazeutischen Herstellern, über 12.400 neuen Produkten (NDCs) und mehr als 275 Apotheken in seine nationale Plattform.
Die KI-gestützte Infrastruktur des Unternehmens zielt darauf ab, die Lieferung von verschreibungspflichtigen Medikamenten zu revolutionieren, indem Hersteller direkt mit Apotheken, Anbietern, Arbeitgebern und Patienten verbunden werden. Die Plattform bietet umfassende Dienstleistungen, darunter Großhandelsvertrieb, digitale Rezeptweiterleitung, Apothekenabgabe sowie Hub-Dienste wie Berechtigungsprüfung, vorherige Genehmigung und Patientenbindung.
- Added 116 new pharmaceutical manufacturer partnerships in Q2 2025
- Expanded product catalog with over 12,400 new NDCs
- Integrated 275+ new pharmacies into the platform
- Platform spans complete prescription journey with comprehensive services
- None.
Insights
Wellgistics Health reports significant Q2 platform growth: 116 new manufacturer partnerships, 12,400+ products, 275+ pharmacies added to its prescription distribution ecosystem.
Wellgistics Health's Q2 2025 operational results demonstrate substantial ecosystem expansion across multiple dimensions. The addition of 116 pharmaceutical manufacturer partnerships represents significant upstream supply chain growth, while 12,400+ new products dramatically expands their formulary. The onboarding of 275+ pharmacies strengthens their downstream distribution network, creating powerful network effects.
This three-pronged expansion strategy is strategically significant for a platform business in healthcare distribution. Each new manufacturer and pharmacy creates exponentially more value for all participants - a classic network effect that strengthens Wellgistics' competitive moat. The company is effectively building critical mass in a typically fragmented sector.
What makes this growth particularly noteworthy is Wellgistics' apparent technology-first approach to pharmaceutical distribution. Their AI-powered infrastructure aims to disintermediate traditional wholesale distribution channels that have historically added cost layers without proportional value. By connecting manufacturers more directly to endpoints, they're positioned to potentially capture margin currently absorbed by legacy middlemen.
The accelerating platform adoption suggests market validation of their model, though the true test will be whether this operational growth translates to revenue and margin expansion in coming quarters. The company's emphasis on "hyper structural transformation" indicates they're prioritizing infrastructure building over immediate profitability - a classic platform strategy focused on long-term market position.
While this release doesn't contain financial metrics, the rate of ecosystem expansion provides a meaningful leading indicator of potential future performance. For a technology platform in healthcare, achieving this scale of network growth is typically a prerequisite to monetization at scale.
TAMPA, FL / ACCESS Newswire / June 25, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a healthcare technology company focused on building the future of prescription access and distribution, today announced significant Q2 2025 operational results-adding 116 new pharmaceutical manufacturer partnerships, over 12,400 new products (NDCs), and 275+ pharmacies to its national platform.
This expansion reflects Wellgistics' accelerating momentum in creating a modern drug ecosystem-one that aims to connect manufacturers directly to pharmacies, providers, employers, and patients through a fully integrated, AI-powered infrastructure designed to streamline fulfillment, reduce costs, and bypass legacy bottlenecks.
"We're in hyper structural transformation mode," said Brian Norton, CEO of Wellgistics Health. "Pharma companies are signaling a shift. They want partners who can deliver speed, visibility, and direct access-not more layers of complexity. Every new manufacturer, every new product, and every new pharmacy is helping us rewire how prescriptions move in this country. We're laying the foundation for real-time, patient-first drug access at national scale."
As Wellgistics continues to advance toward direct-to-patient care programs, the company intends to leverage its expanding distribution, fulfillment, and pharmacy network to support new models of care-aligning pharmaceutical manufacturers with a streamlined path to market while offering patients faster, more transparent prescription access.
The Wellgistics platform spans the full prescription journey-from wholesale distribution and digital Rx routing to pharmacy dispensing and Hub Services including eligibility, prior authorization, adherence tracking, and patient engagement. With thousands of pharmacies on board and manufacturer demand accelerating, Wellgistics seeks to be a vital infrastructure partner for reshaping prescription drug delivery in the U.S.
About Wellgistics Health
Wellgistics Health (NASDAQ:WGRX) is a healthcare technology company built for the
For more information, visit www.wellgisticshealth.com.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health's statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, which are available for review at www.sec.gov.
For more information, please contact:
Media Contact: media@wellgisticshealth.com
Investor Relations: investors@wellgisticshealth.com
Investor Relations Contact:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com
SOURCE: Wellgistics Health, Inc.
View the original press release on ACCESS Newswire
FAQ
How many new manufacturer partnerships did Wellgistics Health (WGRX) add in Q2 2025?
How many new products were added to the Wellgistics (WGRX) platform in Q2 2025?
What services does Wellgistics Health's (WGRX) platform provide?
How many new pharmacies joined Wellgistics (WGRX) platform in Q2 2025?
